Macular Edema Equipment For Medical Specialties
2 equipment items found
-
based in TAIWAN
TLC399 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP), intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration. A Phase I/II safety trial has demonstrated ...
-
Manufactured by Clearside Biomedicalbased in USA
FIRST commercial product developed by Clearside; FIRST approved therapeutic delivered into the suprachoroidal space; FIRST therapy for macular edema associated with uveitis; FIRST uveitis trial using visual acuity change as a primary endpoint (Phase 3 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you